The use of corticosteroids in autoimmune encephalitis. Basic and clinical considerations

Bryan Lester Nahar-González, Ivan David Lozada-Martínez, Yandris Arevalo-Martínez, Loraine Quintana-Pajaro, Silvia Prada-Soto, Teresa Pacheco-Hernandez, William Florez-Perdomo, Yelson Alejandro Picón-Jaimes, Luis Rafael Moscote-Salazar

DOI: 10.33962/roneuro-2021-030
The use of corticosteroids in autoimmune encephalitis. Basic and clinical considerations

B.L. Nahar-González1, I.D. Lozada-Martínez2,3,4, Y. Arevalo-Martínez5, L. Quintana-Pajaro3,5, S. Prada-Soto6, T. Pacheco-Hernandez2, W. Florez-Perdomo3, Y.A. Picón-Jaimes7, L.R. Moscote-Salazar2,3,4

1 Medical and Surgical Research Center, New Jersey, USA
2 Medical and Surgical Research Center, University of Cartagena, COLOMBIA
3 Colombian Clinical Research Group in Neurocritical Care, University of Cartagena, COLOMBIA
4 Latin American Council of Neurocritical Care, Cartagena, COLOMBIA
5 Center for Biomedical Research, University of Cartagena, COLOMBIA
6 Medical and Surgical Research Center, Atlanta, USA
7 Medical and Surgical Research Center, Valencian International University, CHILE

ABSTRACT
Autoimmune encephalitis (AE) is a brain inflammation caused by autoantibodies that target proteins, intracellular and extracellular antigens, triggering damage in the CNS; AE is classified in various syndromes caused by various antibodies, it is a diagnosis of exclusion. Therefore, it has to be differentiated from multiple causes that could unleash encephalitis. However, its treatment is based primarily on immunotherapy, where corticosteroids as immunosuppressive agents, play a key role in the treatment along with other agents.

INTRODUCTION
The immune system, under certain pathophysiological conditions, is capable of producing antibodies against cells, tissues, or organs, triggering known autoimmune diseases [1]. These reactions are often expressed in the central nervous system, for example, autoimmune encephalitis (AD), which is a brain inflammation due to the presence of freely circulating autoantibodies that affect nerve cells [2]. The advent of technologies that have allowed the detection of antibody subtypes, has modified the classification of autoimmune encephalitis, substantially improving the diagnosis, management, and prognosis of these patients [1,2]. However, one of the current challenges consists of
The use of corticosteroids in autoimmune encephalitis

as in early diagnosis and management in low-level hospital institutions, which do not have laboratories or specialized equipment that facilitate this type of exam, so the approach in these cases is general, frequently with the isolated use of corticosteroids [3]. Based on the above, the objective of this manuscript is to present evidence on the role of corticosteroids in the treatment of autoimmune encephalitis, highlighting basic and clinical aspects that translate their understanding and usefulness.

PATHOGENESIS OF AUTOIMMUNE ENCEPHALITIS

AD is brain inflammation produced by the action of autoantibodies directed against cell surface proteins, intracellular and intracellular antigens [2,4]. Various processes such as paraneoplastic syndromes, molecular mimicry, vaccines, or failure of immune tolerance, might trigger the production of autoantibodies against specific antigens that cause disease [1,4]. For this reason, the identification of autoantibodies constitutes a fundamental step to understand the pathophysiological mechanism of autoimmune encephalitis, its complete understanding will allow choosing the appropriate diagnostic tests and treatment [1,4].

Autoimmune encephalitis is classified taking into account the pathophysiological mechanism that produces it (Figure 1). For this reason, the pathogenesis will be addressed, considering grouping antibodies according to the location of their antigens [5-7].

![Figure 1. Autoimmune encephalitis classification according to the pathogenetic mechanism [2,4,6,7].](image)

Paraneoplastic syndromes, in which antibodies "Anti-Hu" are directed against intracellular antigens, primarily tissue such as temporal lobe, cerebellum, brainstem, dorsal roots, and autonomic nervous system [8-9]. In other autoimmune systemic syndromes such as Systemic Lupus Erythematosus, where there are antibodies against phosphorylated ribosomal P proteins, neurological and/or psychiatric manifestations may occur, such as psychosis, with a positive correlation between antibody levels and severity of symptoms [10,11].

The binding of antibodies to antigens, whether at the intracellular or extracellular level, causes alteration of synaptic interactions and prevents the expression of these receptors; if this happens for a long time, irreversible damage to the central nervous system could be generated [12].

CLINICAL MANIFESTATIONS

AD has a wide clinical spectrum in which they can be found from the typical encephalitis with involvement of the limbic system, to complex neuropsychiatric symptoms. These symptoms are related to the type of antibody and the antigen to which it is directed (Table 1) [1,2,5].

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMDA</td>
<td>Psychosis, dystonia, chorea, epilepsy, cognitive impairment, dysautonomia</td>
</tr>
<tr>
<td>AMPA</td>
<td>Psychosis, limbic encephalitis, aggressiveness, hallucinations, sleep disorders</td>
</tr>
<tr>
<td>GAD 65</td>
<td>Stiff Man syndrome, DM1, cerebellitis</td>
</tr>
<tr>
<td>ANNA 1</td>
<td>Cerebellitis</td>
</tr>
<tr>
<td>GABA</td>
<td>Psychosis, epilepsy</td>
</tr>
<tr>
<td>Caspr2</td>
<td>Neuromyotonia, muscle spasm, fasciculations, insomnia, hallucinations</td>
</tr>
</tbody>
</table>

Table 1. Clinical manifestations related to the type of antigen [2,5].

Symptoms despite being variables, in most adolescents and adults evolve in stages, initially, the symptoms may appear similar to a viral infection in which headache and fever are the most common. Later, between days and weeks, neuropsychiatric
symptoms are triggered. These may include psychosis, euphoria, aggression, inappropriate sexual behaviors, fear, panic attacks, and compulsive behaviors, cognitive impairment, seizures (predominantly in pediatric patients) [13], sleep disturbances, developmental and language regression, catatonia, gait instability, and autonomic instability [14,15].

**SUBTYPES OF AUTOIMMUNE ENCEPHALITIS**

Depending on the presence of specific autoantibodies directed against synaptic and neuronal cell surface antigens [2], the following encephalitis subtypes occur:

**Antibodies against intracellular antigens**

**Anti-Hu encephalitis (ANNA-1)**

In Anti-Hu encephalitis (ANNA-1), many patients present with sensory neuropathy, cerebellar degeneration, encephalitis, or encephalomyelitis. Interestingly, this condition is closely related to small cell lung cancer [5]. Other patients with Anti-Hu present with a pattern of encephalitis with greater involvement of the brainstem [16-18] or limbic system [8,18,19].

**Antibodies against intracellular synaptic proteins**

**Anti-GAD65 encephalitis**

In Anti-GAD65 encephalitis (glutamic acid decarboxylase 65 kd), the antibody targets the enzyme required for the synthesis of the neurotransmitter GABA [5,20,21]. It is clinically associated with type 1 diabetes mellitus, cerebellar ataxia, Stiff Man syndrome [22,23] and limbic encephalitis [2,8,18,19]. In the paraneoplastic setting, it is related to paraneoplastic cerebellar degeneration [5].

**Antibodies against extracellular antigens**

**Anti-NMDAr encephalitis**

Anti-NMDAr (N-methyl-D-aspartate receptor) encephalitis represents 20% of autoimmune encephalitis, being the most frequent [2]. It begins with fever, nausea and diarrhea, 2 weeks later psychiatric and / or neurological symptoms begin, progressing rapidly with a tendency to severity, reaching a comatose phase [14,24,25]. Its classic manifestations are: psychosis, agitation, dyskinesias, sleep disorders, mutism, encephalopathy, faciobrachial seizures, dysautonomia, and cognitive impairment [25].

**Anti-LGI1 encephalitis**

Anti-LGI1 encephalitis (glioma-inactivated leucine-1) is responsible for most cases of encephalitis attributed to VGKC1 antibodies, its most frequent symptoms are myoclonus, seizures, hyponatremia, limbic encephalitis and fascio-brachial dystonic seizures [26-28].

**Anti-Caspr2 encephalitis**

Anti-Caspr2 encephalitis is associated with Morvan syndrome and Isaacs syndrome. It may present with confusion and personality change [5,29].

**Seronegative Autoimmune Encephalitis**

A subgroup of patients, due to their clinical manifestations, presents suspicion of autoimmunity, but the antibody detection test is negative, their main symptoms are of a psychiatric nature, including perceptual alterations, catatonia and agitation [1].

**DIAGNOSTIC APPROACH**

The diagnosis of AD is made based on the clinical characteristics, so it should be suspected in any adult or child with the previously mentioned manifestations. Usually, the diagnosis is accompanied by magnetic resonance imaging, electroencephalography, functional neuro imaging, analysis of systemic tumors, and detection of antibodies.

In Magnetic Resonance, the EA may appear as a completely normal image to an abnormal increase in contrast in the cortical or subcortical area of the brain parenchyma. Positron emission tomography, although not performed routinely, can report an increase in frontal-occipital metabolism. This latter finding is related to longstanding [1,2,3,30] disease.

Another useful tool is the detection of autoantibodies in both blood and CSF. One of the most frequent antibodies isolated is the IgG anti-
The use of corticosteroids in autoimmune encephalitis

NMDAr antibody [15]. It should be emphasized that the detection of antibodies in CSF has greater sensitivity and specificity than serum detection [32]. In certain cases, the anti-NMDAr type IgA and IgM may be isolated, but these do not have diagnostic value, however, they are associated with chronic diseases such as schizophrenia [33,34].

In the setting of advanced encephalitis, antibodies tend to remain elevated in CSF, while their titers may be low in serum due to treatment [30,35,36]. The differential diagnosis of AD includes a broad category of psychiatric disorders such as psychosis or schizophrenia (the most common), malignant catatonia, or viral encephalitis. Although not very common, cases of autoimmune encephalitis associated with COVID-19 have been reported [37-39].

**PILLARS OF AUTOIMMUNE ENCEPHALITIS THERAPY**

There are 2 primary goals in AD therapy: reducing inflammation and slowing the development of the disease, which in turn improves symptoms in patients [1]. A cornerstone of treatment is the early use of immunotherapy when there is a high clinical suspicion of AE, even when the presence of neoplasia or the presence of antibodies has not been identified [40]. However, antibody identification is crucial and that leads to a specific treatment. If there is the presence of tumors, resection is an important part of treatment [2,3,6].

**Immunotherapy**

Immunotherapy in AD includes general immunosuppressive agents and others that target phases of pathogenesis [6].

There are 3 lines of treatment; a first-line consisting of steroids, intravenous (IV) immunoglobulin and plasmapheresis (PLEX), a second containing Rituximab and cyclophosphamide, and an alternative therapy that includes agents such as azathioprine, mycophenolate mofetil [1,3,6,41, 42], which are steroid-sparing agents used for maintenance, and tocilizumab for refractory cases [6]. It is important to keep in mind that AE associated with neoplasms has a faster course and is irreversible; in other words, it is difficult for patients to recover even when treatment is started early [43].

In the event of clinical suspicion of AD, empirical treatment should be instituted as quickly as possible, even before the results of antibody tests [40], and may include steroids and/or IV immunoglobulins [5], and if the first-line therapy fails, we should start the second line as quickly as possible. The response to first-line therapy [6] can be observed approximately 2 weeks after starting treatment, so this is the time to take into account for changing therapy, if necessary. However, a significant number of patients with AD will respond to first-line therapy and will have a good outcome within 1–2 weeks after initiation of therapy [3]. Table 2 describes the therapeutic lines available for the management of AD.

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Therapeutic target</th>
<th>Posology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Children</strong></td>
<td><strong>Adults</strong></td>
<td></td>
</tr>
<tr>
<td><strong>First line therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Cytokines, deplete T cells</td>
<td>30 mg / kg up to 1000 mg IV over 3 to 5 days</td>
</tr>
<tr>
<td>Methylprednisolone (solumedrol) [5]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV immunoglobulin</td>
<td>Antibodies and autoimmune mediators</td>
<td>2 g / kg over 2 days, followed by weekly dose for the next 4 weeks**</td>
</tr>
<tr>
<td>Plasmapheresis</td>
<td>Antibodies and autoimmune mediators</td>
<td>1 session every 2 days for 5-7 days</td>
</tr>
<tr>
<td><strong>Second line therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>CD20 + B cells and short-lived plasma cells</td>
<td>375 mg / m2 IV infusion weekly for 4 weeks</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>Lymphocytes (alters DNA crosslinking)</td>
<td>750 mg / m2 IV monthly *** for 3-6 months [3,6]</td>
</tr>
<tr>
<td><strong>Alternative therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Lymphocytes (blocks nucleotide synthesis)</td>
<td>Initially 1-1.5 mg / kg once daily or divided twice daily, target 2-3 mg / kg / day</td>
</tr>
</tbody>
</table>
Mycophenolate | Lymphocytes (inhibits IMP dehydrogenase) | Initially 500mg twice daily, target 1000mg twice daily
---|---|---
Tocilizumab | Cytokines | Initially 4 mg/kg, followed by an increase of 8 mg/kg per month based on clinical response
IL-2 (aldesleucina) | Cytokines | 1.5 million IU/day, 4 subcutaneous injections 3 weeks apart each other

** If a synaptic antibody/cell surface disorder is detected, administer IVIG, plasmapheresis, and/or steroids. If a synaptic / cell surface antibody is determined and significant symptoms are shown, provide first-line therapy if not provided [5].

** In severe cases, it is given more frequently with the first 2-3 cycles given every 2 weeks [1]

*** Until improvement is observed [5].

Table 2. Therapeutic lines for autoimmune encephalitis [1,5,6].

Symptomatic treatment
It is composed of sedative drugs, to induce and maintain sleep; drugs to manage agitation and emotional instability such as benzodiazepines, clonidine, antiepileptics, choral hydrate, or others, which usually offer benefits [3]. Treatment in the presence of seizures must be carried out aggressively with antiepileptics. The majority of patients do not require long-term seizure treatment [44].

Corticosteroids and its mechanism of action in encephalitis
Corticosteroids are the most important first-line agents in AD therapy [3,6], being beneficial in multiple autoimmune disorders [5,6]. Although there is no strong evidence for the superiority of corticosteroids over other therapies, they are the first treatment option, followed by intravenous immunoglobulins and PLEX [6].

Mechanism of action
Corticosteroids are a group of drugs with anti-inflammatory characteristics that act on intracellular glucocorticoid receptors [6], interrupting the transcription of multiple pro-inflammatory genes [6,7] that are activated in chronic inflammatory diseases [7] and that encode cytokines, chemokines, adhesion molecules, inflammatory enzymes, receptors, and proteins [6,7]. They influence almost all cytokines, thus depleting T cells, inhibiting Th1 differentiation, macrophage dysfunction, and eosinophil apoptosis [6]. In high concentrations, they have activity on the synthesis of anti-inflammatory proteins and induce post-transcriptional or post-genomic effects [6,7].

Advantages
They penetrate the brain, an advantage it has over other drugs such as Rituximab, which does not cross the blood-brain barrier (BBB) [6], so they are given as empirical therapy in suspected AD [45]. In addition, they modulate the BBB [3] restoring its integrity and controlling cerebral edema [6].

Goldenholz et al [45] state that corticosteroids as a low-cost therapy could play a role in treatment algorithms for suspected AD cases [45]. Similarly, Prasad et al [46] that in AD a good response to steroids has been shown even when no confirmed serology suggests an autoimmune basis [46].

Disadvantages
Steroids have low specificity on antibody-mediated immune processes, so their efficacy has been debated in AD since they slightly decrease the number of circulating B cells, not contributing much to antibody titers; in addition, they have been associated with systemic side effects [6]. It should be noted that side effects are more frequent with the use of oral steroids than with intravenous [1]. Corticosteroids can also cause or increase the psychiatric symptoms associated with AD, and some clinical studies even suggest neurotoxic and neurodegenerative effects of corticosteroids after chronic exposure [6].

Management
Steroids are administered IV or orally, the former being delivered as “pulse doses” (Table 2). This therapy is not standard and there are no clear treatment regimens [1]. Nosadini et al [47] carried out a systematic review on immune therapy in AD, with the aim of generating evidence on the use, type of treatment and efficacy, finding that as first-line
therapy, it is used in the majority of cases (more than 50% of patients with AD) [47].

**CONCLUSION**

Autoimmune encephalitis is a syndrome whose pathogenesis involves different immunological pathways against neuronal surface antigens, for which immunotherapy with various immunosuppressive agents has been proposed as treatment; with a relatively accepted answer. Corticosteroids are consolidated as first-line agents in the treatment of AD, however, better quality studies are needed to demonstrate their superiority over other therapies, and thus identify the safest and most effective system.

**REFERENCES**


